Comparative effectiveness and safety of upadacitinib, abrocitinib and dupilumab in treatment-resistant prurigo nodularis
In a small, imbalanced multicentre cohort, JAK1 inhibitors showed faster itch relief and greater lesion clearance signals than dupilumab, with meaningful improvements in quality of life.
Authors
- Gözde Ulutaş Demirbaş (ORCID: https://orcid.org/0000-0002-1468-4605)
- Mustafa Esen (ORCID: https://orcid.org/0000-0002-4736-9142)
- Abdullah Demirbaş (ORCID: https://orcid.org/0000-0002-3419-9084)
- Esin Diremsizoğlu (ORCID: https://orcid.org/0000-0001-9824-481X)
Institutions
- Dicle University (TR)
- Kocaeli Üniversitesi (TR)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1093/ced/llaf518
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00